|
Session 119-Poster Abstracts
Pharmacokinetics, Pharmacodynamics, and Pharmacogenetics of NRTI and NNRTI
Wednesday, 2-4 pm; Poster Hall |
600
 |
Association of ABCC10 Polymorphisms with Nevirapine Plasma Concentrations in the German Competence Network for HIV/AIDS
Neill Liptrott*1,2, S Pushpakom1,2, C Wyen3, J Rockstroh4, S Mauss5, H Knechten6, N Brockmeyer7, E Hopper-Borge8, D Back2, A Owen2, and German Competence Network for HIV/AIDS
1Natl Inst of Hlth Res, Natl Biomedical Res Ctr for Microbial Disease, Liverpool, UK; 2Univ of Liverpool, UK; 3Univ of Cologne, Germany; 4Univ of Bonn, Germany; 5Ctr for HIV and Hepatogastroenterology, Düsseldorf, Germany; 6PZB, Aachen, Germany; 7St Josef Hosp, Bochum, Germany; and 8Fox Chase Cancer Ctr, PA, US |
| 601 |
Integrating Pharmacogenetics and Population Pharmacokinetic Analysis: Simulating the Impact of CYP2B6 516G>T for 400 mg Once-daily Nevirapine Dosing
Alessandro Schipani*1, T Mahungu1,2, C Wyen3, S Esser4, N Brockmeyer4, S Khoo1, M Johnson2, G Davies1, A Owen1, and D Back1
1Univ of Liverpool, UK; 2Royal Free NHS Trust, London, UK; 3Univ of Cologne, Germany; and 4Univ of Essen, Germany |
602
|
Nevirapine Pharmacokinetics When Initiated at 200 mg or 400 mg Daily in HIV-1 and TB Co-infected Ugandan Adults on Rifampicin
Mohammed Lamorde*1,2, P Byakika-Kibwika1,2,3, V Okaba-Kayom1, F Kalemeera1, M Ryan2, P Coakley4, M Boffito5, D Back6, S Khoo6, and C Merry1,2,7
1Infectious Disease Inst, Makerere Univ, Kampala, Uganda; 2Univ of Dublin Sch of Med, Trinity College, UK; 3Infectious Disease Network for Treatment and Res in Africa, Kampala, Uganda; 4Royal Coll of Surgeons of Ireland, Dublin; 5St Stephens Ctr, Chelsea and Westminster Hosp, London, UK; 6Univ of Liverpool, UK; and 7St James’s Hosp, Dublin, Ireland |
603
|
Nevirapine Increases Lumefantrine Exposure in HIV-infected Patients
Tamara Kredo*, J S Van der Walt, K Mauff, P Smith, K Cohen, G Maartens, and K Barnes
Univ of Cape Town, South Africa |
604
|
Concentrations of Efavirenz in Hair Correlate Strongly with 24-hour Intensive Pharmacokinetic Measurements and with Virologic Outcomes
Monica Gandhi*1, N Ameli1, S Gange2, K Anastos3, P Bacchetti1, M Cohen4, M Young5, H Minkoff6, Y Huang1, R Greenblatt1, and Women’s Interagency HIV Study
1Univ of California, San Francisco, US; 2Johns Hopkins Univ Bloomberg Sch of Publ Hlth, Baltimore, MD, US; 3Albert Einstein Univ, Bronx, NY, US; 4Cook County Hosp, Chicago, IL, US; 5Georgetown Univ, Washington, DC, US; and 6City of Hope Natl Med Ctr, Los Angeles, CA, US |
605
|
Assessment of Bioequivalence of Tenofovir, Emtricitabine, and Efavirenz Fixed-dose Combination Tablet Compared with a Compounded Oral Liquid Formulation Derived from the Tablet
Jennifer King*, M McCall, A Cannella, M Markiewicz, A James, and E Acosta
Univ of Alabama at Birmingham, US |
606
|
Lack of Interaction between Etravirine and Raltegravir plus Darunavir/Ritonavir When Combined in Treatment-experienced Patients: A Substudy of the ANRS 139 TRIO Trial
A Barrail-Tran1, Y Yazdanpanah2, C Fagard3, C Colin3, C Piketty4, C Katlama5, D Descamps6, J-M Molina7, G Chêne3, Anne-Marie Taburet*1, and ANRS 139 Study Group
1Hosp Bicetre, AP-HP, Paris, France; 2Hosp Tourcoing, France; 3INSERM U897, Bordeaux, France; 4Hosp Georges Pompidou, AP-HP, Paris, France; 5Hosp Pitie-Salpetriere, AP-HP, Paris, France; 6Hosp Bichat Claude Bernard, AP-HP, Paris, France; and 7Hosp Saint Louis, AP-HP, Paris, France |
| 607 |
Thymidylate Synthase Polymorphisms Determine Stavudine Triphosphate Intracellular Levels in HIV-1-infected Patients Treated with a Stavudine-based Antiretroviral Regime
Pere Domingo*1, M C Cabeza1, A Pruvost2, F Villarroya3, M D Gutierrez1, F Vidal3, G M Mateo1, J Muñoz1, J C Domingo3, and M Baiget1
1Hosp de la Santa Creu i Sant Pau, Autonomous Univ of Barcelona, Spain; 2CEA, Gif sur Yvette, France; and 3Univ of Barcelona, Spain |
|
